Survodutide: A Tracking Guide for a GLP-1 and Glucagon Dual Agonist

Survodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim for obesity and for MASH (metabolic dysfunction-associated steatohepatitis). The GLP-1 arm reduces appetite while the glucagon arm targets liver fat and energy expenditure. In the Phase 3 SYNCHRONIZE-1 obesity trial, survodutide produced up to about 16.6 percent mean weight loss at 76 weeks versus 3.2 percent for placebo, and it has generated strong liver data, including the LIVERAGE MASH program and a Breakthrough Therapy designation.

Survodutide is investigational and not approved. This is an educational tracking guide, not medical advice or a recommendation.

What it does

• Combines GLP-1 appetite suppression with glucagon-driven effects on the liver
• Drives fat loss in obesity trials
• Reduces liver fat, inflammation, and fibrosis markers in MASH studies

Typical protocol shape

In the SYNCHRONIZE trials, survodutide is titrated upward over weeks to a maintenance dose to limit GI intolerance, given once weekly by subcutaneous injection. Doses cited anywhere reflect the trial protocol only, not a personal target.

What to track daily

• Appetite, portion sizes, and fullness
• Nausea, vomiting, diarrhea, or constipation
• Resting heart rate, which dual agonists can raise

What to track weekly

• Bodyweight under consistent conditions
• Waist circumference
• Injection-site tolerance
• Grip strength or a simple lift to watch for muscle loss during rapid loss

Bloodwork worth doing

• Liver enzymes and, where relevant, liver imaging or fibrosis markers, given the MASH focus
• Fasting glucose and HbA1c
• Lipid panel over time

Realistic expectations

The obesity and liver data are promising but come from trials, not real-world use. Titration matters for tolerability, and weight loss is gradual. As with any rapid loss, some can be lean mass, so protein and resistance training belong in the tracking sheet.

Common mistakes

• Treating investigational data as if the drug were approved and characterized for daily use
• Ignoring GI intolerance during titration
• Neglecting muscle-preserving habits during weight loss

Safety notes

Survodutide is not approved and its full risk profile is still being defined. Expect GLP-1 class GI effects and heart-rate changes, and note that glucagon agonism adds metabolic effects worth monitoring. Anyone using it outside a trial is outside the evidence base and should be under medical supervision.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.